ALMOF.US Alphamab Oncology
- Market cap
- USD 986M
- P/E
- -
- P/B
- 3.93x
- ROE
- -6.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ALMOF.US undervalued?
Graham numberThe Graham number of Alphamab Oncology cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Alphamab Oncology fundamental analysis
No fundamental analysis for Alphamab Oncology yet.
Alphamab Oncology stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Alphamab Oncology
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal gr…
Full company profileAlphamab Oncology financial statements
Alphamab Oncology annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 167M | 219M | 640M | 566M |
| Gross Profit | 123M | 164M | 580M | 503M |
| Operating Income | -408M | -306M | 114M | -136M |
| EBITDA | -256M | -129M | 253M | -41.8M |
| Net Income | -326M | -211M | 166M | -114M |
| EPS | -0.35 | -0.22 | 0.17 | -0.12 |
| Balance Sheet | ||||
| Total Assets | 2.12B | 2.14B | 2.24B | 2.10B |
| Total Liabilities | 560M | 465M | 410M | 386M |
| Shareholders' Equity | 1.56B | 1.67B | 1.83B | 1.71B |
| Cash & Short-term Investments | 1.07B | 1.09B | 1.11B | 259M |
| Cash Flow | ||||
| Operating Cash Flow | -300M | -203M | 212M | -122M |
| Capital Expenditure | 130M | 36.2M | 21.8M | 31.6M |
| Free Cash Flow | -430M | -239M | 191M | -153M |
| Ratios | ||||
| ROE | -20.9% | -12.6% | 9.1% | -6.7% |
| ROA | -15.4% | -9.9% | 7.4% | -5.4% |
| Net Profit Margin | -195.2% | -96.3% | 26.0% | -20.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Alphamab Oncology dividends
Alphamab Oncology has not paid dividends in the last 4 fiscal years.
Who owns Alphamab Oncology
- Insiders 50.40%
- Institutions 3.19%
- Public & others 46.41%
- Shares outstanding 965M
- Free float 482M
Alphamab Oncology company profile
- Company name
- Alphamab Oncology
- Ticker
- ALMOF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 515
- Fiscal year end
- December
- Address
- No. 175 Fangzhou Road, Suzhou, China, 215127
- Phone
- 86 512 6285 0800
- Website
- alphamabonc.com
About Alphamab Oncology
Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. It offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of solid tumors, lung cancer, and breast cancer; JSKN022, a bispecific single-domain antibody; JSKN027, a bispecific ADC that is Phase I clinical trial; JSKN021; KN019; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops JSKN029, a pre-clinical stage product for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Alphamab Oncology management
9- Dr. Ting Xu Ph.D.Founder, Executive Chairman & CEO · born 1973
- Ms. Yang LiuCOO & Executive Director · born 1972
- Mr. Fei Wang CPAChief Financial Officer · born 1978
- Dr. Hongwei WangChief Technology Officer
- Mr. Yumin WanVice President of Government Affairs & Public Relations · born 1972
- Dr. Mike Liu M.B.A., Ph.D.Senior Vice President of Business Development · born 1966
- Mr. Jing HanChief Commercial Officer · born 1973
- Ms. Lok Yee Chan A.C.I.S., A.C.S.Joint Company Secretary · born 1990
- Ms. Rui JiangJoint Company Secretary